iQure Pharma
Skillman, US · Founded 2019 · Delaware corporation · 4 known investors
Find your way into iQure Pharma
120 people in our graph share verified history with the iQure Pharma team — schools, employers, funds. One of them is your warm intro.
Ben Wirzunlockedknows Peter Schiemann · together at INSEAD (overlapped)
×10knows the team · via INSEAD
knows the team · via University of Basel
iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset is an orally available EAAT2 positive allosteric modulator in early clinical development, with epilepsy as the first validation path.
Founders & leadership
iQure Pharma was founded in 2019 by Peter Schiemann.
PS
Peter SchiemanninCo-Founder & Board MemberPeter Schiemann holds a PhD in molecular and cell biology and has over two decades of experience in pharmaceutical development and manufacturing, including roles at Roche in clinical supplies and quality assurance, consulting at PricewaterhouseCoopers on R&D strategy, and founding multiple biotech and consulting firms. He co-founded iQure Pharma in 2019, a clinical-stage biotech developing therapeutics for CNS and pain disorders.
PZ
Pawel ZolnierczykinChief Executive Officer, Director
Investors · 4
Also in the syndicate · 2
OKG CapitalVentura BioMed
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 5 rounds · 2023–2026
▶$650KraisedJun 2026 · 1 investors · OtherRule 506(b)
▶$650KraisedJun 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $4M
- Amount sold
- $650K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedNov 2025 · 14 investors · OtherRule 506(b)
▶$1.5MraisedNov 2025 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.5M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJan 2025 · 2 investors · OtherRule 506(b)
▶$1.4MraisedJan 2025 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$220KraisedApr 2024 · 7 investors · OtherRule 506(b)
▶$220KraisedApr 2024 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Amount sold
- $220K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedOct 2023 · 13 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedOct 2023 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Uniqure9 shared keywordsuniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
IQVIA6 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Iecure6 shared keywordsiECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
Onkure Therapeutics Inc5 shared keywordsOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Companies competing with iQure Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does iQure Pharma do?
- iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset is an orally available EAAT2 positive allosteric modulator in early clinical development, with epilepsy as the first validation path.
- Who founded iQure Pharma?
- iQure Pharma was founded by Peter Schiemann in 2019.
- Who are iQure Pharma's investors?
- iQure Pharma's investors include Keiretsu Forum, Ventura BioMed Investors.
- How much funding has iQure Pharma raised?
- iQure Pharma has disclosed $5.3M raised across 5 rounds.
- Where is iQure Pharma headquartered?
- iQure Pharma is headquartered in Skillman, US.